Summary In the present study, we investigated the effect of inteferon-gamma (IFN-y) on 
IFN-y is an inflammatory cytokine that is capable of enhancing anti-tumour immune response by inducing the surface expression of different antigens, including intercellular adhesion molecule-I (ICAM-1) and HLA class II, on tumour cells (Mortarini et al., 1960; Azuma et al., 1992) . The signal transduction pathways used by IFN-y to modulate antigen expression have been examined previously, but are still not well understood. However, a constant finding has been the activation of the Ca2" phospholipid-dependent protein kinase C (PKC) by IFN-y in both normal and neoplastic cells (Fan et al., 1988; Griffiths et al., 1990; Renkonen et al., 1990; Hansen et al., 1993) . In the U937 macrophage cell line (Klein et al., 1990) and in human endothelial cells (Renkonen et al., 1990) , IFN-y-induced PKC activation has been shown to be accompanied by inositol 1, 4, 4, formation. These studies suggest that IFN-y receptor activation results in the cleavage of phosphatidylinositol bisphosphate into diacylglycerol and Ins 1,4,5-P3 by phospholipase C (Downes & Macphee, 1990 We have recently shown that IFN-y can activate PKC in the human renal carcinoma cell line CaKi-1 (Hansen et al., 1993) . However, this activation was not related to induced ICAM-1 antigen expression, indicating that alternative signalling pathways may be stimulated, including other Ca2'-dependent kinases. To our knowledge, there are no previous studies which have investigated the ability of IFN-y to increase [Ca2+] i and Ins 1,4,5-P3 formation in human renal carcinoma cells.
In the present study we examined the role of Ca2+ and Ins 1,4,5-P3 as secondary messengers during IFN-y signalling in CaKi-1 cells. Furthermore, the possible role of a Ca2 + dependent mechanism during IFN-7-induced antigen expression was evaluated, since this adhesion molecule can augment anti-tumoral immunity.
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Materials and methods

Reagents
Human recombinant IFN-(1 -5 x I07 units per mg of protein) designated IFN-y 4A was purchased from Amersham International (Denmark). The calcium ionophore, 4-bromocalcium ionophore A23187 (bromo-A23187), diltiazem, EGTA (N,N,N',N'-tetraacetic acid), 4, trimethoxybenzoic acid 8-(diethylamino)octyl ester], R24571 (calmidazolium), W7 (N-6-aminohexyl-5-chloro-l-naphthalenesulphonamide hydrochloride) and compound 48/80 (condensation products of N-methyl-p-methoxy-phenethylamine with formaldehyde) were obtained from Sigma (St Louis, MO, USA). IFN-y was stored at 2-4°C diluted to 104 or 105unitsml-' in McCoy's 5a medium containing 10% fetal bovine serum (FBS) (Gibco, Paisley, UK). Bromo-A23 187 and R24571 were dissolved in dimethylsulphoxide (DMSO) and 1 mg ml-' stock solutions were stored at -80°C. All other drugs were dissolved in water and I mgml-1 stock solutions were stored at -20°C. The final concentration of DMSO did not exceed 0.3% and cultures containing appropriate quantities of diluents were run in parallel to control for minor effects.
Cell cultures
The human renal carcinoma cell line CaKi-1 was kindly provided by J. Fogh (Novo Nordisk, Gentofte, Denmark) and was originally isolated and characterised by the late J. Fogh (Memorial Sloan Kettering, Rye, NY, USA; Fogh & Trempe, 1975) . The cells were maintained in MCoy's Sa medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 2 mM glutamine (Gibco) and 100 IU ml-' penicillin/streptomycin (Gibco). Cultures were incubated at 37'C in a 95% air, 5% carbon dioxide humid incubator.
Intracellular Ca2" measurements Confluent monolayers of CaKi-1 cells were detached with 3 mM EGTA in Hanks' balanced salt solution without Ca2+/ Mg2+/phenol red pH 7.4 (HBSS) (Gibco) for 20 min at 37C, washed twice and allowed to settle for 2 h in McCoy's 5a medium. Cells from 2-3 flasks (1 x 107) were pooled in McCoy's 5a medium plus 0.5% bovine serum albumin (BSA) (Sigma) and loaded with 2 liM of the fluorescent dye, fura-2/ AM (Molecular Probes, OR, USA). The rise in [Ca2+] , was measured as previously described for fibroblasts (Bouchelouche et al., 1988) . The time course of changes in fluorescence was measured with a Hitachi F 4000 spectrofluorimeter using a single excitation and emission wavelength of 340 and 510 nm respectively. Drugs were added as indicated.
Radioligand assay measurement of Ins 1,4,5-P3 Cellular Ins 1,4,5-P3 was measured initially using a competitive binding assay (Chaliss et al., 1988; Palmer et al., 1989) (Amersham International, Denmark) . Briefly, confluent CaKi-l cells in 75 cm2 flasks (I07 cells) were incubated with 10 mM inositol in 4 ml of McCoy's for 1 h, washed with McCoy's and subsequently incubated in 4 ml of McCoy's with 10 mm inositol and 10 mM lithium chloride for 30 min at 37°C. After rewashing, cells were stimulated with IFN-y in 4 ml of McCoy's at the indicated times and concentrations. The reaction was stopped with 2 ml of ice-cold 15% trichloroacetic acid (TCA). The cells were then transferred to cryotubes (Nunc, Roskilde, Denmark), frozen in liquid nitrogen and kept at -80°C. After thawing, samples were centrifuged at 1,000 g for 15 min at 4°C. The supernatants were decanted and the pellets resuspended in ice-cold 15% TCA for 20 min. The pellet suspension was then mixed, centrifuged at 1,000 g for 15 min at 4°C and pooled with the corresponding supernatants. The TCA supernatants were extracted four times with 5 ml of anhydrous diethylether and adjusted to pH 7.5 with sodium bicarbonate. Sample aliquots (100 1l) were mixed with equal amounts of D-myo-[3H]Ins 1,4,5-P3 and bovine adrenal Ins 1,4,5-P3 binding protein, vortexed and incubated for 15 min on ice. The samples were then centrifugated at 1,000 g for 30 min at 4°C. The supernatants were decanted and the pellets were resuspended in scintillant. 
Analysis of inositol phosphates by column chromatography
To confirm the binding assay, Ins 1,4,5-P3 was measured by fast protein liquid chromatography (FPLC) on a Pharmacia Mono-Q anion-exchange column as described by Chew and Brown (1986) and Bouchelouche et al. (1990) . Briefly, for each reaction condition 107 CaKi-1 cells in 75 cm2 flasks were incubated with D-myo-[3H]inositol (5 I.tCi ml-') for 12 h in an atmosphere of 5% carbon dioxide at 37°C. Cells were then incubated for 30 min with 10 mM cold inositol and 10 mM lithium chloride in McCoy's at 37°C. After incubation cells were washed three times with McCoy's, reincubated with 10 mM lithium chloride in McCoy's for 10 min and stimulated with IFN-y in 4 ml of McCoy's. The reaction was stopped with 2 ml of ice-cold 15% TCA. The cells were then transferred to cryotubes and TCA supernatants were extracted as described for the radioligand assay measurements of Ins 1,4,5-P3 (see above). Sample aliquots (200 pl) containing the water-soluble inositol phosphates were separated using the Mono-Q anion-exchange column equilibrated with an ammonium formate (M)/formic acid (0.1 M) gradient and an FPLC (Pharmacia) system (Chew & Brown, 1986) . Fractions of 3 ml were collected and radioactivities measured by liquid scintillation counting. Three major peaks of radioactivity were eluted from the column. These peaks coeluted with 3H-labelled inositol standards (Du Pont/Dupharma, Denmark) of inositol 1-monophosphate (Ins I-P), inositol 1,4-bisphosphate (Ins 1,4-P2) and Ins 1,4,5-P3 (Chew & Brown, 1986; Bouchelouche et al., 1990 (Schlager & Adams, 1983) .
Total protein synthesis measurement
The effect of calcium antagonist and protein inhibitors on total protein synthesis was analysed as described by Ritchie et al. (1991) Assay ofprotein kinase A activity Recent data suggest that cAMP-elevating agents can induce ICAM-1 antigen expression in human glioma cells (Bouillon et al., 1992) . In order to evaluate the significance of cAMPdependent protein kinase (PKA) inhibition by the two modulators of Ca2'-binding proteins used in this study, namely R24571 and W7, PKA activity was assayed upon IFN-y stimulation. CaKi-1 cells were grown to a confluent monolayer in 75 cm2 flask with McCoy's 5a medium supplemented as described above. Following stimulation of the cells (107) with IFN-y, treatment was stopped by decanting the medium and rinsing the monolayers twice in ice-cold PBS. After rinsing, flasks were maintained at 4°C while cells were gently scraped in 4 ml of ice-cold extraction buffer (5 mM EDTA, 50 mM Tris, pH 7.5). The cells were homogenised for 15 strokes on ice in a precooled Dounce homogeniser and left on ice for 30 min. To remove cellular debris the homogenate was centrifuged at 2,000 g for 10 min. The supernatants were removed and assayed for PKA activity. PKA was measured by the incorporation of 32p from 100I JM [y-32P]ATP (1 X 105d.p.m. nmol ', Amersham) into each sample in the presence or absence of cAMP (40 nM) with or without the heat-stable rabbit skeletal muscle PKA inhibitor protein PKI (6-22)NH2 (4 gM in 50 mM Tris, pH 7.5) using the PKA assay system (3128SA, Gibco, Paisley, UK). Substrate phosphorylation in the presence of cAMP reflected the total amount of PKA in each sample. The background (substrate phosphorylation in the presence of PKI) was subtracted from each sample, and PKA activity was expressed as the percentage of activated PKA per total PKA. fura-2/AM-fluorescence was measured continuously with time. Figure la shows TMB-8 (Malagodi & Chiou, 1974; Owen & Villereal, 1982 indicates mobilisation of Ca'+ from intracellular stores. Therefore, we examined the ability of IFN-y to increase intracellular levels of Ins 1,4,5-P3 (Table I) . Table I shows that IFN-y caused a concentration-dependent rise in Ins 1,4,5-P3 after I min stimulation. IFN-y at 10 units ml-' was enough for an almost maximal Ins 1,4,5-P3 production. Figure 2 illustrates the time course for Ins 1,4,5-P3 formation after stimulation with 500unitsml-' IFN-y. Maximal levels were reached within 1 min. This corresponds with the time for maximal [Ca2'], increase after stimulation with 500 units ml-' IFN-y (Figure la) . In order to confirm the radioligand assay experiments (Table I) , inositol phosphate formation was further analysed by FPLC (Table I1 ). As shown in Table II . IFN-y stimulated a significant increase in Ins 1-P and Ins 1,4,5-P3. There was a slight increase in Ins 1.4,-P,. but this did not reach significant levels. Figure 3 shows a typical elution pattern of water-soluble inositol phosphates from Mono-Q columns. Thus, the FPLC analysis supports the radioligand assay experiments. CaKi-l cells were incubated with 10, 100 or 500 units ml-' IFN-y for 24 h. The data in Figure 5a show that IFN-y caused an increase in ICAM-1 antigen expression above control value at 100 and 500 units ml'. IFN-y at 10 units ml-' had no effect on ICAM-1 antigen expression, although this dose yielded a clear [Ca2+] i rise ( Figure la) and an almost maximal Ins 1,4,5-P3 production (Table I) . To investigate the role of calcium during ICAM-1 antigen induction we incubated cells with bromo-A23187 (0.5 tIM) for 24 h. Bromo-A23187 significantly raised ICAM-1 antigen expression after 24 h (Figure 5b ). Furthermore, combining full doses of IFN-y (500 units ml-') and bromo-A23187 for 24 h significantly increased ICAM-1 antigen expression as compared with either agent alone ( Figure Sb) . This increment showed a slight synergy with a mean MFI of 272, since the sum of the two agents mean increment was 187 MFI.
Statistics
Effects of inhibition of calcium transients on IFN-y-induced ICAM-I antigen expression
To determine the functional significance of extracellular calcium, cells were pretreated for 60 min at 37°C with the calcium channel blocker diltiazem (I jiM) or the Ca2+ chelator EGTA (I mM), before addition of IFN-y (500 units ml-') for 24 h. Figure Sc shows that, in the presence of diltiazem or EGTA, the mean MFI decreased from 531 ± S C):
to 508 ± 7 and 493 ± 23 respectively. Despite statistical significance, these differences represent a weak non-conclusive decline in ICAM-1 antigen expression. The two antagonists had no effect on basal ICAM-1 antigen expression when used alone. To examine whether cellular calcium stores contribute to an increase in ICAM-1 antigen expression, CaKi-l cells were pretreated with TMB-8 (75 tM) for 60 min at 37°C followed by addition of IFN-'y (500 units ml-') for 24 h. TMB-8 significantly reduced IFN-y-induced ICAM-1 antigen expression from 579 ± 1 (MFI) to 514 ± 1 (MFI). This represents a partial reduction of only 11%. TMB-8 had no effect on basal ICAM-1 antigen expression.
Effect of R24571 and W7 on IFN-y-induced ICAM-1 antigen expression Since ICAM-1 antigen expression may be induced by a
[Ca2+]i rise via activation of Ca2"-binding proteins, CaKi-l cells were pretreated with R24571, an anti-mycotic agent, and W7, a naphthalenesulphonamide, both potent inhibitors of Ca2'-binding proteins including PKC and calmodulin (Gietzen et al., 1981; Tanaka et al., 1983) . Incubation of cells with R24571 (10 tiM) or W7 (40 !LM) for 60 min at 37°C before addition of IFN-y (500 units ml-') for 24 h significantly reduced IFN-7-induced ICAM-1 antigen expression ( Figure Se and f) . However, when the total protein synthesis was taken into account for normalising ICAM-1 antigen expression, R24571 had no inhibitory effect, while W7 only inhibited ICAM-1 antigen induction from 579 ± 1 (MFI) to 526 ± 22 (MFI), less than 10% ( Figure 6 illustrates representative traces from the FACS analysis indicating a highly homogeneous CaKi-I cell population with minimal variation.
Effect of IFN-y on PKA activity The control level of PKA activity in CaKi-1 cells was 6.0 ± 1.7%. This level was unaffected by stimulation with IFN-y (500 units ml-') for 15, 30 and 60 min, which yielded a PKA activity between 5.6 ± 1.4% and 7.8 ± 1.5%. These results support the hypothesis that the inhibitory effect of W7 on IFN-y-induced ICAM-1 antigen expression was not caused by PKA inhibition. Hence, although cAMP-elevating agents can enhance ICAM-1 antigen expression, possibly via PKA (Bouillon et al., 1992) , and although the potent calmodulin antagonist W7 may act upon PKA at 40 liM (Hidaka et al., 1984) , this was unlikely to be the case in CaKi-I cells.
Discussion IFN-y has been used alone or in combination with IFN-c as an immunotherapeutic agent in patients with renal cell carcinoma (Heicappell & Ackermann, 1990) . One of the main anti-tumoral effects of IFN-y is the induction of cell-surface antigens, including ICAM-1, by activating different intracellular signal transduction pathways (Azuma et al., 1992; Bouillon et al., 1992; Hansen et al., 1993) . In different cell types IFN-y has been shown to activate PKC and/or increase Ins 1,4,5-P3 formation, indicating stimulation of the phosphatidylinositol-Ca2+ signal transduction pathway (Klein et al., 1990; Renkonen et al., 1990) . We have recently demonstrated PKC activation as well as ICAM-1 antigen induction upon IFN-y treatment of CaKi-I cells (Hansen et al., 1993 redistribution (Malagodi & Chiou, 1974; Owen & Villereal, 1982) , and since Ins 1,4,5-P3 is a natural releaser of Ca2+ from intracellular stores (Downes & Macphee, 1990) , IFN-ystimulated formation of Ins 1,4,5-P3 was examined. We found a signficant increment in Ins 1,4,5-P3 using two independent methods, a radioligand assay (Table I and Figure 2 ) and FPLC (Table II and Figure 3) , which suggests that IFN-y-induced redistribution of intracellular calcium may be mediated by this phosphatidylinositol metabolite. Usually high-performance liquid chromatography (HPLC) is used for separation of inositol phosphates (Burgess et al., 1985; Turk et al., 1986; Klein et al., 1990) . However, the FPLC system appears to be superior in its ability to rapidly separate inositol phosphates while maintaining good resolution (Florholmen et al., 1989) .
Often, only cell viability by dye exclusion or 'signs of toxicity' not otherwise specified are described when protein inhibitors are used in the study of antigen expression in cell cultures (Rothlein et al., 1988; Griffiths et al., 1990; Pedrinaci -A et al., 1990) . However, this may be misleading, since total protein synthesis can be inhibited despite normal cell viability, as shown for R24571 and W7 in CaKi-1 cells (Figure 4 ). The inhibition of total protein synthesis by these two inhibitors is a non-specific effect in relation to ICAM-1 antigen expression. Normalising ICAM-1 antigen expression to total protein synthesis revealed a markedly reduced effect, with only W7 reaching significant inhibition (Figure 5e and f). Similar findings have been obtained with the PKC inhibitors H7 and staurosporine (Ritchie et al., 1991; Bouillon & Audette, 1993) . Unfortunately, compound 48/80 could not be used because the cell viability was affected at even low doses.
The enhancement of ICAM-1 antigen expression in CaKi-l cells by IFN-y as assessed by FACS was approximately 1.3-to 1.4-fold. Although this represents a weak response as compared with other cell types, such as melanoma cells (Scheibenbogen et al., 1993) , the FACS profile showed a highly homogeneous cell population ( Figure 6 ). Furthermore, our data clearly demonstrated that IFN-y-induced Ins 1,4,5-P3 formation was not coupled to ICAM-1 antigen expression because 10 units ml-' IFN-y was enough for an almost maximal Ins 1,4,5-P3 formation (Table I) , whereas it had no effect on ICAM-1 antigen expression (Figure 5a ). Also, in the presence of either diltiazem, EGTA or TMB-8, the IFN-ystimulated ICAM-l antigen expression decreased by less than 15% (Figure 5c and (Figure 5f ). The naphthalenesulphonamide derivative W7 is a potent calmodulin antagonist, but may act upon several protein kinases at high concentrations. (Tanaka et al., 1983 : Hidaka et al.,1984 . These include the cAMP-dependent PKA and PKC, besides its actions via calmodulin on calmodulin-dependent proteins. Since both cAMP-elevating agents and PKC activators can enhance ICAM-1 antigen expression (Griffiths et al., 1990; Bouillon et al., 1992 ) the W7 effect could have been ascribed to PKA and/or PKC inhibition, and not just calmodulin antagonism. However, IFN-y did not stimulate PKA activity in CaKi-l cells. Furthermore, although IFN-y activates PKC in CaKi-l cells as assayed by both histone and acetylated myelin basic protein peptide (4-14) substrate phosphorylation, inhibition of PKC with H7 and sphingosine had no effect on IFN-yinduced ICAM-1 antigen expression (Hansen et al., 1993 (Brady et al., 1985) . As discussed above, the non-specific effect of W7 on total protein synthesis was accounted for by normalising ICAM-l antigen expression.
Our results partly agree with earlier studies on IFN-y signalling in other cell types. In human endothelial cells, IFN-y activates PKC and induces Ins 1,4,5-P3 (Renkonen et al., 1990) . Using similar radioligand assay conditions for Ins 1,4,5-P3 quantitation as in our study, Renkonen et al. (1990) showed a maximal rise after 10 min of stimulation, with no significant rise within 1 min. This discrepancy, as compared with CaKi-1 cells, may relate to the malignant transformation itself or to the different embryonal origins of the cell lines. However, Renkonen et al. (1990) did not confirm their measurements of inositol trisphosphate formation with other independent assays, but were able to show a significant 1.4- fold increase in the efflux of 45Ca2" 5 min after IFN-y stimulation. Furthermore, although W7 was shown to decrease IFN-7-induced ICAM-1 antigen expression, this decrease was less than 20% and also not normalised to total protein synthesis. Therefore, the W7 effect may well have been non-specific. Our data are consistent with the findings of Klein et al. (1990) , who demonstrated that IFN-y caused a significant increase in Ins 1,4,5-P3 formation within 1 min in U937 cells, using a identical radioligand assay and HPLC.
The IFN-y-induced rise in Ins 1,4,5-P3 was correlated to a rise in [Ca2] i. In agreement with our study, W7 had little or no effect on IFN-y-induced antigen expression in U937 cells. In contrast, Ina et al. (1987) have shown that IFN-y induces a rise in Ca2+ and HLA class II antigen expression in HL-60 cells, which again can be efficiently blocked by W7. In general, the reports on IFN-y signalling agree that this cytokine can activate PKC and raise [Ca2+] i by increasing Ca2+ influx and/or by generating Ins 1,4,5-P3. However, the effect of PKC inhibitors such as H7 or calmodulin inhibitors such as W7 on IFN-y-induced antigen expression depends on the applied cell line and antigen under study (Ina et al., 1987; Griffiths et al., 1990; Klein et al., 1990; Renkonen et al., 1990; Hansen et al., 1993) .
